Lyrica Articles
Tapentadol ER has advantages over Lyrica in reducing diabetic neuropathy pain intensity
21 March 2012
Global pain management drugs market to see moderate growth as generic share continues to rise
24 November 2011
Pfizer out-licenses neratinib to Puma Biotech; stops Lyrica epilepsy trial on good efficacy
7 October 2011
Pfizer’s Lyrica meets endpoint in Ph III study of central neuropathic pain after spinal cord injury
22 June 2011
Impax now to co-promote Pfizer’s Lyrica; updates on APEX-PD trial; Pfizer in deal with Stemgent on reagents
16 April 2010
UK’s NICE sets national standard for neuropathic pain drug treatments in non-specialist NHS settings; guidance on angina
25 March 2010
The “new” Pfizer sees 4th qtr s2009 sales and profit rocket, but 2010 guidance disappoints
4 February 2010
Prioritized pipeline at “new” Pfizer marks important milestone for the company’s R&D organization
28 January 2010
World fibromyalgia syndrome market to grow at a CAGR of 9.2% for the next seven years, reaching $1.8 billion by 2015, forecasts Global Data
11 January 2010
US FDA calls for more data on Pfizer's Lyrica for generalized anxiety disorder; sells drug rights to TMC
24 December 2009
Pfizer 2009 3rd-qtr earnings beats forecasts, but sales weaken
21 October 2009
US Court imposes record fine and forfeiture of $1.3 billion for Pfizer unit’s fraudulent marketing of Bextra
19 October 2009
Pfizer
21 May 2009
GSK/Xenoport drug fails Ph II DPN study
28 April 2009
CHMP meeting sees good news for AZ, but not for Teva
24 April 2009
Lyrica fares well vs venlafaxine-ER in GAD
30 March 2009
Data on withdrawn drugs was faked; says hospital
16 March 2009
Winston Pharma gets orphan status for civamide
2 March 2009
Anti-epileptics to get suicide warnings in USA
22 December 2008
Pfizer's 3rd-qtr 2008 profit triples due to Exubera write-off; revenues flat at $12B
27 October 2008
DEA block to US e-Rx adoption set to end
30 June 2008
Pfizer's Lyrica reduces fibromyalgia pain
28 April 2008
Pfizer sees 4th-qtr 2007 profits decline, but still beats forecasts; revenue rises 4%
28 January 2008
Northwestern sells Lyrica royalty rights for $700M
24 December 2007
Pfizer
23 July 2007
FDA approves Pfizer's Lyrica for fibromyalgia
2 July 2007
Pfizer's Lyrica reduces fibromyalgia pain 50%
14 May 2007
Pfizer's 1st-qtr profits tumble 17.5%
30 April 2007
Strong efficacy data for Pfizer's Lyrica
4 December 2006
EASD panels recommend insulin acceptance, and highlight shortfalls in DPNP therapy
25 September 2006
Pfizer's Lyrica approved by EC for central neuropathic pain
25 September 2006
Israeli basket update c'tee recommends another 16 new technologies
4 September 2006
Pfizer
31 July 2006
Proximagen licenses candidate CNS drugs
5 June 2006
Pfizer's Lyrica cleared for GAD in EU
3 April 2006
Pfizer's Lyrica gets CHMP nod as GAD drug
6 February 2006
US orphan status for TheraQuest's TQ-1017
22 August 2005
Added indication for Pfizer's Lyrica in USA
20 June 2005
Flexible dosage as good as fixed for Pfizer's Lyrica
13 June 2005
Scotland OKs Femara, rejects other drugs
14 March 2005
Pfizer's Lyrica cuts seizure rate in half
21 February 2005
US volume Rx sales rise 8.3% in 2004
21 February 2005
New product launches in 2004
31 January 2005
Pfizer launches Lyrica in the UK
20 September 2004
Neuropathic pain mkt "to reach $4.83B by 2010"
13 September 2004
FDA gives Pfizer's Lyrica mixed response
13 September 2004
Pfizer's Lyrica gets CPMP nod in EU
5 April 2004
Pfizer submits US NDA for pregabalin
10 November 2003
Little optimism in neuropathic pain market; report
25 February 2002
Update - Celebrex and Vioxx panel review on COX-2 inhibitors
15 February 2001
Pfizer forecasts strong revenue growth in 2001-2002 at R&D meeting
14 December 2000
W-L To Stay Independent As Product Line Improves
30 April 1998
W-L To Stay Independent As Product Line Improves
24 April 1998
Showing 1-87 of 87 articles
- 1
- UK's NICE does U-turn, recommending Zytiga as Janssen cuts price
- ABPI chief asks: Is saving money more important than saving lives?
- Ambitious growth targets set for Bayer Healthcare in 2014
- GlaxoSmithKline buys full control of Cellzome
- Ophthalmic drugs market set for $18.7 billion value in 2012, says Visiongain
